Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AC Immune SA - Common Stock (NQ:ACIU)

3.190 +0.040 (+1.27%)
Streaming Delayed Price Updated: 3:02 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AC Immune SA - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Unusual volume stocks in Friday's session ↗
Unusual volume stocks are being observed in Friday's session. 
Via Chartmill
News headline image
Why Is AC Immune Stock Up Over 23% Today? ↗
ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 
Via Stocktwits
News headline image
AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2025 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board
From AC Immune SA
Via GlobeNewswire
News headline image
First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine
From AC Immune SA
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Participate in Upcoming Investor Conferences
From AC Immune SA
Via GlobeNewswire
News headline image
Eliminating Some Screened Stocks ↗
Commodity prices regularly swing 25-30% or more in any given year. When this happens, the financial health of these firms can get dicey very quickly, given the amount of capital investment it requires... 
Via Talk Markets
Topics Stocks / Equities
News headline image
AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome
From AC Immune SA
Via GlobeNewswire
News headline image
S&P 500 Moves Lower; US Crude Oil Inventories Increase ↗
 
Via Benzinga
Topics Stocks
News headline image
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients ↗
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease. 
Via Benzinga
News headline image
Hillenbrand Posts Better-Than-Expected Earnings, Joins Beazer Homes, Tapestry, Walt Disney And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune to Present at the Jefferies 2024 London Healthcare Conference
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
From AC Immune SA
Via GlobeNewswire
News headline image
AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024
From AC Immune SA
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.